elecoglipron (AZD5004) / Eccogene, AstraZeneca - LARVOL DELTA

CT-SY22-1: Symposium - AZD5004, A Novel Oral Small Molecule GLP-1 Receptor Agonist: Overweight/Obesity (VISTA) and Type 2 Diabetes (SOLSTICE) Phase 2 Trial Results (ADA 2026) - No abstract available

P2 data • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

SOLSTICE: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled and Open-Label Active Comparator Study to Evaluate the Efficacy, Safety, and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus (ADA 2026) - No abstract available

Clinical • P2b data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

VISTA: A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD5004 in Participants Living with Obesity or Overweight with Comorbidity (ADA 2026) - No abstract available

Clinical • P2b data • Metabolic Disorders • Obesity

A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open

A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years (clinicaltrials.gov) - P1 | N=64 | Not yet recruiting | Sponsor: AstraZeneca

New P1 trial

A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: AstraZeneca

New P1 trial

Eccogene Announces Positive Topline Results from Phase 1b Trial of Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, in Adult Participants Living with Obesity/Overweight, with or without Type 2 Diabetes in China (Businesswire) - "Elecoglipron was generally well-tolerated, with a safety profile consistent with the GLP-1RA class...The PK profile of elecoglipron in Chinese participants was similar to prior data generated from global clinical studies...Cohort A (obesity/overweight without T2DM): Compared with the placebo group, participants treated with elecoglipron achieved a clinically meaningful weight reduction at week 16; Cohort B (obesity/overweight + T2DM): Participants in this cohort who received elecoglipron achieved a clinically meaningful reduction in mean HbA1c at week 16 compared with those who received placebo."

P1 data • PK/PD data • Obesity • Type 2 Diabetes Mellitus

AstraZeneca reveals oral GLP-1 scored phase 2 wins but holds back weight loss data (FierceBiotech) - "AstraZeneca is taking its oral GLP-1 drug into phase 3 on the back of a pair of midstage weight loss wins, despite remaining tight-lipped on how the candidate actually performed...The company disclosed in its full-year 2025 earnings results (PDF) this morning that both trials hit their primary endpoints, and elecoglipron...will be progressing into phase 3 development this year...However, the pharma is holding back on revealing the level of weight loss the drug induced in each study—a make-or-break factor in the highly competitive obesity space—until the American Diabetes Association conference in June."

New P3 trial • P2 data • Obesity • Type 2 Diabetes Mellitus

A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants (clinicaltrials.gov) - P1 | N=51 | Completed | Sponsor: AstraZeneca | Active, not recruiting ➔ Completed

Trial completion

SOLSTICE: Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus. (clinicaltrials.gov) - P2 | N=406 | Completed | Sponsor: AstraZeneca | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Phase Ib Study of AZD5004 in Chinese Participants With Overweight/Obesity With or Without Type 2 Diabetes Mellitus (clinicaltrials.gov) - P1 | N=45 | Completed | Sponsor: Eccogene | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants (clinicaltrials.gov) - P1 | N=51 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting

Enrollment closed

VISTA: Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity (clinicaltrials.gov) - P2 | N=310 | Completed | Sponsor: AstraZeneca | Active, not recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants (clinicaltrials.gov) - P1 | N=49 | Completed | Sponsor: AstraZeneca | Active, not recruiting ➔ Completed

Trial completion

A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Dec 2025 ➔ Mar 2026 | Trial primary completion date: Dec 2025 ➔ Mar 2026

Trial completion date • Trial primary completion date

A Phase Ib Study of AZD5004 in Chinese Participants With Overweight/Obesity With or Without Type 2 Diabetes Mellitus (clinicaltrials.gov) - P1 | N=45 | Active, not recruiting | Sponsor: Eccogene | Trial completion date: May 2026 ➔ Dec 2025

Trial completion date • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants (clinicaltrials.gov) - P1 | N=49 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting

Enrollment closed

AZD5004: Data from P2b VISTA trial (NCT06579092) for obesity in H1 2026 (AstraZeneca) - H1 and Q2 2025 Results: Data from P1 trial (NCT06988553) in participants with overweight/obesity with/without T2D in H1 2026

P1 data • P2b data • Obesity

A Study in Healthy Participants to Investigate Relative Bioavailability of AZD5004 in Three Solid Oral Formulations (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: AstraZeneca | Active, not recruiting ➔ Completed

Trial completion

A Phase Ib Study of AZD5004 in Chinese Participants With Overweight/Obesity With or Without Type 2 Diabetes Mellitus (clinicaltrials.gov) - P1 | N=45 | Active, not recruiting | Sponsor: Eccogene | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Study in Healthy Participants to Investigate Relative Bioavailability of AZD5004 in Three Solid Oral Formulations (clinicaltrials.gov) - P1 | N=16 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting

Enrollment closed

A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open

A Phase Ib Study of AZD5004 in Chinese Participants With Overweight/Obesity With or Without Type 2 Diabetes Mellitus (clinicaltrials.gov) - P1 | N=45 | Recruiting | Sponsor: Eccogene | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Eccogene Announces First Patient Dosed in Phase 1b Trial of AZD5004/ECC5004, a Novel Oral GLP-1 Receptor Agonist, in China (GlobeNewswire) - "Eccogene...announced that the first patient has been dosed in a Phase 1b clinical trial of AZD5004/ECC5004 in China. The earlier Phase 1 trial of AZD5004/ECC5004 was conducted in the U.S. only and this trial in China is a key milestone to support local regulatory requirements. AZD5004/ECC5004 is an investigational oral small molecule GLP-1 receptor agonist, which is currently being investigated for the treatment of type 2 diabetes and obesity or overweight with at least one comorbidity."

Trial status • Obesity • Type 2 Diabetes Mellitus

SOLSTICE: Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus. (clinicaltrials.gov) - P2 | N=406 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus